Tofacitinib versus tocilizumab in the treatment of biological-naïve or previous biological-failure patients with methotrexate-refractory active rheumatoid arthritis

OBJECTIVES: To compare effectiveness between tofacitinib and tocilizumab treatments for biological disease-modifying antirheumatic drug (bDMARD)-naïve patients or previous bDMARD-failure patients with active rheumatoid arthritis (RA) refractory to methotrexate (MTX). METHODS: We used two ongoing rea...

Descripción completa

Detalles Bibliográficos
Autores principales: Mori, Shunsuke, Urata, Yukitomo, Yoshitama, Tamami, Ueki, Yukitaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103932/
https://www.ncbi.nlm.nih.gov/pubmed/33958440
http://dx.doi.org/10.1136/rmdopen-2021-001601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103932/
https://www.ncbi.nlm.nih.gov/pubmed/33958440
http://dx.doi.org/10.1136/rmdopen-2021-001601

Ejemplares similares